3,4-Methylenedioxy-N-propargylamphetamine

3,4-Methylenedioxy-N-propargylamphetamine (MDPL) is a lesser-known psychedelic drug and a substituted amphetamine. MDPL was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown.[1] MDPL causes few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPL.

3,4-Methylenedioxy-N-propargylamphetamine
Names
Preferred IUPAC name
N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-yn-1-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C13H15NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h1,4-5,8,10,14H,6-7,9H2,2H3
    Key: LRYUTPIBTLEDJJ-UHFFFAOYSA-N
  • CC(NCC#C)Cc1ccc2OCOc2c1
Properties
C13H15NO2
Molar mass 217.268 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Legality

edit

United Kingdom

edit

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

edit

References

edit
  1. ^ MDPL entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.